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Abstract
Malignant glioma is the most common primary brain tumor, and its ability to invade the surrounding brain pa-
renchyma is a leading cause of tumor recurrence and treatment failure. Whereas the molecular mechanisms
of glioma invasion are incompletely understood, there is growing evidence that cytoskeletal–matrix interactions
contribute to this process. Fascin, an actin-bundling protein, induces parallel actin bundles in cell protrusions
and increases cell motility in multiple human malignancies. The role of fascin in glioma invasion remains unclear.
We demonstrate that fascin is expressed in a panel of human malignant glioma cell lines, and downregulation of
fascin expression in glioma cell lines by small interfering RNA (siRNA) is associated with decreased cellular attach-
ment to extracellular matrix (ECM) and reduced migration. Using immunofluorescence analysis, we show that
fascin depletion results in a reduced number of filopodia as well as altered glioma cell shape. In vitro invasiveness
of U251, U87, and SNB19 glioma cells was inhibited by fascin siRNA treatment by 52.2%, 40.3%, and 23.8% re-
spectively. Finally, we show a decreased invasiveness of U251-GFP cells by fascin knockdown in an ex vivo rat
brain slice model system. This is the first study to demonstrate a role for fascin in glioma cell morphology, motility,
and invasiveness.
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Introduction
Malignant gliomas are the most common primary brain tumors [1].
Currently, surgery and radiation therapy followed by treatment with
temozolomide is the treatment protocol of choice for patients with
glioblastoma multiforme [2,3]. However, despite advanced multimodal
treatment, the median life expectancy for patients with glioblastoma
multiforme is approximately 14 months with less than 5% of patients
alive at 5 years after diagnosis [4,5]. Although systemic metastases of
malignant gliomas are relatively rare, the highly infiltrative nature of
glioma cells that invade into surrounding brain parenchyma is a major
cause of treatment failure and tumor recurrence [6,7]. Glioma invasion
is a multifactorial process consisting of glioma cell interactions with
normal cellular constituents such as astrocytes, neurons, and endothe-
lial cells, interactions with the extracellular matrix (ECM), proteolysis
of ECM components, and migration [8].
To migrate, glioma cells must modify their shape and rigidity to
interact with the surrounding environment [9]. Typically, a migrating
glioma cell will remodel its cytoskeleton to form cellular protrusions
and focal adhesions at the leading edge, and generate tensile forces to
move the cell body forward. Cellular protrusions known as filopodia
are considered essential processes in cell migration because they func-
tion as sensors of the external microenvironment and as plasma
membrane extensions that form initial contacts with the ECM.
The rearrangement of actin microfilaments into strong parallel actin
bundles within or near filopodia is a key component of the migration
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process [10–13]. Reorganization of the actin microfilamentous sys-
tem has previously been associated with alterations in glioma mor-
phology and invasiveness [14].
Several actin-binding proteins have been described including
α-actinin, tropomyosin, fimbrin, villin, and fascin [11]. Fascin is a
key actin-bundling protein that provides rigidity to filopodial bundles
[13,15]. Fascin was first isolated from sea urchin egg extracts [16], and
then identified in Drosophila [17] and in human B-lymphocytes [18].
Fascin has been shown to be expressed at high levels in the brain, ovary,
and testis [19]. In the brain, fascin expression has been localized to neu-
rons, glial cells, and endothelial cells [19–22]. Fascin colocalizes with
filopodia, microspikes, lamellopodia, and stress fibers [20,23]. Addi-
tionally, fascin has been shown to localize to lamellipodia and filopodia
in growth cones of cultured neurons [12,18]. These findings suggest
that fascin may play an important role in the formation of actin-based
structures, such as filopodia and lamellipodia, and in the migratory be-
havior of cells.
Fascin expression is increased in different types of cancers includ-
ing breast, lung, ovary, esophagus, kidney, and colon [24–33]. In ad-
dition, high fascin expression has been observed in many transformed
cells and carcinoma cell lines [15,24,26,29,34]. Cancer cells expres-
sing high levels of fascin exhibit morphologic characteristics, such
as increased membrane protrusions and migration ability. However,
little is known about the role of fascin in human brain tumors. Recently,
two studies reported the relationship between fascin expression and
human gliomas [35,36]. Both studies demonstrate that an increase in
fascin expression is associated with increasing tumor grade in glial tu-
mors. To date, no studies have examined the consequences of fascin
manipulations in experimental glioma cell systems. Accordingly, to de-
termine if fascin plays a role in the migratory capacity of glioma cells,
we have used small interfering RNAs (siRNA) to suppress the expres-
sion of fascin in glioma cells. Here we report our results on fascin
knockdown on glioma cell proliferation, adhesion, migration, and inva-
sivenevess in vitro and in an ex vivo rat brain slice model system.
Material and Methods
Cell Culture and Extracellular Matrix
The permanent, well-characterized human glioma cell lines U251,
U87, SNB19, U138, T98, and U118 were received from the Amer-
ican Type Culture Collection (Manassas, VA). The U343 cell line was
obtained from Brain Tumor Research Center, University of California
(San Francisco, CA). U251-GFP, a glioma cell line stably expressing
green fluorescence protein (GFP), was provided by Michael Berens
(The Translational Genomics Research Institute, Phoenix, AZ). Glioma
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and cul-
tured at 37°C, 5% CO2 in a humidified chamber. Normal human as-
trocytes were purchased from Clonetics (East Rutherford, NJ) and
maintained in ABM media containing 3% FBS, 0.1% ascorbic acid,
0.5% recombinant human epidermal growth factor, 0.1% GA-1000,
0.25% insulin, and 1% l-glutamine (all from Clonetics). The human
ECM proteins laminin, vitronectin, fibronectin, and collagen type IV
were obtained from Sigma (St. Louis, MO).
Small Interfering RNA Preparation and Transfections
Small interfering RNA (siRNA) duplexes specific for Fascin1 were
designed according to Elbashir et al. [37]. Two different Fascin siRNA
sequences were used: Fs1, corresponding to 113 to 133 bp after the
start codon of the Fascin1 gene (5′ GCAGCCTGAAGAAGAAGCA),
and Fs2, corresponding to 1340 to 1360 bp after the start codon of
the Fascin1 gene (5′ CTCCTGTGGACTTCTTCTTTT). The 21-nt
RNA was purchased from Eurogentec (San Diego, CA) in deprotected
and desalted forms. As a control for off-target effects caused by RNA
interference, nontargeting siRNA, designed to have at least four mis-
matches to any human and mouse species, was used (Dharmacon,
Lafayette, CO). Transient transfections of siRNA (50 nM final con-
centration) against Fascin1 were carried out using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Cells were plated at 60% confluency in
DMEM containing 10% serum without antibiotics and transfections
were carried out 24 hours later. Lipofectamine 2000 was diluted in
serum-free DMEM for 5 minutes and the siRNA was diluted in serum-
free DMEM. The two mixtures were combined and incubated for
20 minutes at room temperature to enable transfection complex forma-
tion. The complexes were subsequently added to the cells. Transfections
with Lipofectamine 2000 alone served as controls. Maximal depletion
was achieved by day 3 after transfection, and cells were assayed at
72 hours after transfection. Fascin expression was determined by western
blot analysis using an anti–human fascin monoclonal antibody (1:1000;
DakoCytomation, Carpinteria, CA).
Western Blot Analysis
Total cell lysates were prepared in a lysis buffer (50 mM Tris pH
7.4, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl) with a cocktail
of protease inhibitors (Roche Diagnostics, Basel, Switzerland). Lysates
were cleared by centrifugation and mixed with SDS sample buffer con-
taining Tris pH 6.8, 2% SDS, glycerol and β-mercaptoethanol. The
protein concentration was estimated by Lowry method using DC Pro-
tein Assay Kit (Bio-Rad, Hercules, CA) and 10 μg of protein extracts
were separated by SDS-PAGE, and transferred to polyvinyldifluoride
membranes (Millipore, Bedford, MA). The membranes were subse-
quently blocked with 5% skim milk in TBS–T (50 mM Tris pH
7.5, 150 mM NaCl, and 0.1% Tween 20) for 1 hour at room temper-
ature and incubated overnight at 4°C with the primary antibodies de-
scribed above. A monoclonal antibody against the human transferrin
receptor (1:1000; Zymed, South San Francisco, CA) was used on the
same blot and served as a loading control. The membranes were sub-
sequently incubated at room temperature for 1 hour with horseradish
peroxidase–linked goat anti–mouse IgG (Bio-Rad, Hercules, CA) and
analyzed using Western Blotting Luminol Reagent (PerkinElmer Life
Sciences, Boston, MA).
Cell Viability Assay
Cell viability was determined using the colorimetric MTS assay.
Cells transiently transfected with two different siRNA oligonucleo-
tides were trypsinized, counted and resuspended in DMEM with
10% FBS at 6 hours after transfection. The cells were plated in
96-well dishes at a density of 5000 cells/well and were allowed to
adhere overnight. Cells were transfected with Lipofectamine 2000–
complexed fascin siRNA or nontargeting siRNA. Cells were tested in
quadruplicate with MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (Pro-
mega, Madison, WI)] to assess cell viability at 24 and 72 hours
after transfection. The MTS assay was performed according to the
manufacturer’s instructions. MTS coupled with an electron-coupling
reagent (phenazine ethosulfate) was added to each well of cells and
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incubated at 37°C in a humidified chamber for 1 hour. Absorbance
of the reaction was measured at 490 nm using a microtiter plate reader
(VersaMax; Molecular Devices Corp., Sunnyvale, CA). The quantity
of formazan product, as measured by absorbance, is directly propor-
tional to the number of living cells. Absorbance was plotted as a per-
centage of the control value. All experiments were repeated in triplicate
and repeated three independent times.
Cell Attachment Assay
The cell attachment assay was performed as described previously
[37,38] with modifications. Ninety-six–well plates were incubated at
4°C overnight with different ECM proteins (laminin and fibronectin
at 10 μg/ml, collagen type IV at 50 μg/ml, and vitronectin at 1 μg/ml).
The unbound sites were blocked with 0.1% BSA in PBS for 1 hour
at 37°C. Control dishes were prepared by blocking with BSA alone.
Glioma cells were detached, resuspended in serum-free medium at
72 hours after transfection, then plated at 5 × 104 cells/well on
ECM protein- or BSA-coated plates. The cells were allowed to adhere
for 3 hours at 37°C and 5% CO2 in a humidified chamber. Unattached
cells were removed by washing with PBS three times, and the remain-
ing cells were fixed with 4% paraformaldehyde and stained with 0.5%
crystal violet. The excess stain was washed away with water then air-
dried overnight. The crystal violet bound to the attached cells was
solubilized with 1% SDS and the absorbance of each well was measured
at 595 nm using a microtiter plate reader (Molecular Devices Corp.).
All experiments were repeated three times with five replicates.
Cell Migration Assay
Cell migration assays were performed using the microliter-scale ra-
dial monolayer assay as described previously [6,14,39,40]. Briefly,
10-well Teflon-coated slides (CSM Inc., Phoenix, AZ) were coated
with different ECM proteins and 0.1% BSA as described above.
Cells transfected with siRNA for Fascin1 or nontargeting oligonucle-
otide were collected 24 hours after transfection and seeded through a
cell sedimentation manifold (CSM Inc.) at 3000 cells/well to estab-
lish a circular confluent monolayer, 1 mm in diameter, at the center
of the substrate-coated well. Photographs were taken 16 hours after
plating and a circle of best-fit circumscribing the cells was drawn.
The cells were allowed to migrate for a 24-hour period, and another
circle circumscribing the newly migrated cells was made. The average
migration rate was calculated as the change in the diameter of the
circle circumscribing the cell population over a 24-hour period (mi-
crometers per 24 hours). Photomicrographs were taken with an inverted
microscope (Leica DM IRE2; Leica Microsystems, Bannokburn, IL)
and analyzed using image analysis software (Scion Image, Frederick,
MD). All experiments were repeated in five replicates and experiments
were repeated three times.
Cell Invasion Assay
A cell invasion assay was carried out using modified Boyden Cham-
bers consisting of Transwell-precoated Matrigel membrane filter
inserts with 8 μm pores in 24-well tissue culture plates (BD Bio-
sciences, Bedford, MA) as described previously [40]. Two days after
transfection with siRNA, 4 × 104 cells were plating onto the top of
the chamber in DMEM with 5% FBS and the bottom chamber was
filled with DMEM containing 20% FBS as a chemoattractant. After
24 hours of incubation in a 5% CO2 humidified chamber at 37°C,
noninvading cells were removed by wiping the upper surface of the
membrane with a cotton swab, and the filter membrane was fixed
with 4% paraformaldehyde and stained with 0.5% crystal violet.
The degree of invasion was quantified by counting the cells that
had migrated through the membrane in at least six random fields
(total magnification, ×200) per filter. Experiments were repeated
three times in triplicate.
Ex Vivo Brain Slice Invasion Assay
The ex vivo rat brain slice model system was modified from the
organotypic culture methods reported previously [40–43]. Briefly,
the brain tissue was prepared from 4-week-old male Wistar rats
(Charles River Laboratories Inc., Wilmington, MA). After admin-
istration of isoflurane anesthesia, the cerebrum was removed and
cut vertically to the base in 400-μm sections using a tissue slicer
(EMS 4000; Electron Microscopy Science, Hatfield, PA). The brain
slices were transferred to the upper chamber of a transwell insert
and placed on top of the 0.4-μm micropore polycarbonate filter
(BD Biosciences) in a six-well tissue culture plate. The brain slices
were incubated at least 24 hours before cell seeding at 37°C and
5% CO2 in a humidified chamber in DMEM with 10% FBS,
100 U/ml penicillin, 100 μg/ml streptomycin, and 2.5 μg/ml am-
photericin B. Three days after transfection with siRNA, U251-
GFP cells were trypsinized and resuspended in serum-free medium
to 2 × 108 cells/ml, and 105 glioma cells (0.5 μl transfer volume)
were placed on the center of the putamen. The cells were allowed
to invade into the brain slice for 72 hours. Six brain slices were used
in each experiment. To quantitate glioma cell invasion, the brain slice
was fixed overnight in 4% paraformaldehyde at 4°C, and fluorescent
imaging was taken at 10× magnification using an inverted laser con-
focal microscope (LSM 510 META; Carl Zeiss Inc., Thronwood,
NY). To assess the depth of invasion in control and fascin siRNA–
transfected cell populations, serial sections were obtained every
10 μm downward from the top surface to the bottom of the slice after
72 hours. The LSM 510 software (Carl Zeiss Inc.) was used to calcu-
late the total area of GFP-stained cells in each section and the extent of
glioma cell invasion was defined as the depth of penetration (in μm)
after 72 hours to which the invading cells penetrated the brain slice as
described previously [40]. The animal protocol described here was ap-
proved by the Institutional Animal Care Committee. All experiments
were repeated three times.
Immunofluorescence and Confocal Microscopy
Cells transfected by siRNA were plated onto coverslips precoated
with laminin (10 μg/ml) 24 hours after transfection. At 72 hours
after transfection, cells were washed three times with PBS and fixed
with 4% paraformaldehyde for 10 minutes and permeabilized for
5 minutes with 0.5% Triton X-100 in PBS at room temperature. Non-
specific binding was blocked by 1% BSA in PBS for 1 hour at room
temperature. Subsequently, cells were incubated with an anti–fascin
monoclonal antibody (1:200; DakoCytomation) for 1 hour. After
washing, cells were then incubated with Alexa Fluor 488– (Molecular
Probes, Eugene, OR) conjugated goat anti–mouse IgG secondary anti-
bodies for 30 minutes at room temperature. For double labeling with
F-actin, cells were coincubated with Texas Red-X phalloidin (1:50
dilution; Molecular Probes). A Zeiss Axiovert 200M Spinning Disk
confocal microscope (Carl Zeiss Inc.) installed with a Hamamatsu
Back-Thinned EM-CCD camera (Hamamatsu, Bridgewater, NJ)
was used to visualize fluorescence.
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Statistical Analyses
Data are expressed as mean ± standard error (SE). Statistical anal-
yses were performed with Student’s t test and Mann-Whitney U test.
A P value of < .05 was considered statistically significant.
Results
Fascin Expression in Glioma Cell Lines and Fascin Silencing
by siRNA Transfection
Western blot analysis was performed on all the different glioma cell
lines including U138, T98, U251, U87, SNB19, U343, and U118 as
well as normal human astrocytes. All glioma cells tested and normal
human astrocytes showed fascin expression (Figure 1A). Of the cell
glioma cell lines examined, we selected three, U251, U87, and
SNB19, for further study as they were comparable in terms of fascin
expression levels and were well characterized previously in terms of
in vitro growth kinetics.
Fascin knockdown was achieved following transient transfection
with two different fascin siRNA duplexes (Figure 1B). In all ex-
periments, a nontargeting oligonucleotide was used to exclude non-
specific off-target effects of RNA interference. Fascin knockdown
was observed following 24 hours after siRNA transfection, and
reached maximum depletion at 72 hours after transfection (Fig-
ure 1C ). Therefore, subsequent experiments such as adhesion,
migration, invasion, and immunofluorescent studies were performed
72 hours after transfection to analyze the functional effects of fas-
cin depletion.
Fascin Downregulation and Glioma Cell Viability
An MTS cell viability assay was used to examine the effects of
fascin knockdown on glioma cells. At 72 hours after transfection,
cell viability was unaffected in U251 and SNB19 glioma cells, and
minimally affected in U87 cells (13% decrease in cell viability com-
pared to untransfected and nontargeting siRNA controls) (data
not shown).
Fascin Knockdown Reduces Filopodia Formation in
Glioma Cells
Immunofluorescence was used to examine the effects of fascin
knockdown on cell morphology. Cells were seeded on laminin-coated
coverslips given that previous studies have shown laminin to be the
most permissive ECM substrate for glioma cell motility [6,44]. Fas-
cin localized to the perinuclear cytoplasm and actin-rich membrane
ruffles at the leading edge (Figure 2). SNB19 and U251 cells showed
Figure 1. Expression of fascin protein in glioma cell lines and fascin knockdown by siRNA. (A) Western blot analysis of fascin expression
in astrocytoma cell lines and normal human astrocytes. (B) Fascin expression following transfection with siRNA for fascin1 in U251, U87,
and SNB19 cell lines. (C) Fascin knockdown by siRNA in U251 cells reaches an optimum elimination at 72 hours after transfection.
Expression of human transferrin receptor served as a loading control. NHA, normal human astrocytes; NT, nontargeting siRNA; TfR,
human transferrin receptor, Fs1 and Fs2, two different fascin1 knockdown sequences used.
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well-organized lamellipodia. Filopodia were also observed at the lead-
ing edge especially in SNB19 glioma cells. In contrast to untrans-
fected cells, we observed a decrease in the formation of membrane
ruffles in fascin-depleted SNB19 and U251 glioma cells. U87 cells
changed cell shape somewhat from typical spindle form of untrans-
fected cells to more polygonal appearances after fascin knockdown.
Following fascin knockdown, there was a significant reduction in
filopodia formation especially for U87 and SNB19 glioma cells (Fig-
ure 3). Filopodia that remained after fascin depletion were of shorter
length when compared to controls.
Fascin Elimination Decreases Glioma Cell Adhesion
Given that filopodial formation was significantly inhibited follow-
ing fascin knockdown, and that filopodia play an important role in
cell–ECM adhesion, we predicted that fascin depletion may affect
glioma cell adhesion. To determine the effects of fascin knockdown
on cell–ECM adhesion, we used different purified ECM macromo-
lecules as substrates for glioma adhesion. Glioma cell lines studied
demonstrated different affinities for adhering to ECM macromole-
cules. In general, glioma cell adhesion was greatest in all cell lines
examined when laminin and collagen type IV were used as substrates.
Glioma cell adhesion to vitronectin and fibronectin was similar to
that of BSA in all three glioma cell lines (Figure 4). The ability of
the glioma cell lines to adhere to the different ECM substrates was
strongly inhibited by fascin knockdown (Figure 4). These data sug-
gest that, in addition to loss of filopodia by fascin knockdown,
glioma cells demonstrate a decreased adhesive capacity when com-
pared to controls. In addition, the data indicate that fascin-dependent
adhesion is not attributable to a single ECM macromolecule, as the
percentage inhibition of adhesion due to siRNA is similar across all
substrates examined.
Fascin Elimination Decreases Migration in Glioma Cells
To determine if fascin plays a role in glioma cell migration, radial
migration assays were performed with different purified ECM macro-
molecules over a 24-hour period. Similar to the results observed in
the adhesion study, the migration rate of all three glioma cell lines
was enhanced on ECM substrates. After fascin knockdown, all three
glioma cell lines showed a significant decrease in migration rate; the
migration rate of U251 was decreased on laminin, collagen type IV,
and vitronectin by 47.0% (P < .01), 24.7% (P < .01), and 16.3%
(P < .05), respectively; U87 migration rate was decreased on laminin
and collagen type IV by 47.9% (P < .01) and 24.2% (P < .01), re-
spectively; the migration rate of SNB19 was decreased on laminin, col-
lagen type IV, vitronectin, and fibronectin by 49.8% (P < .01), 39.7%
(P < .01), 28.2% (P < .01), and 28.0% (P < .01) by fascin knock-
down, respectively (Figure 5).
Fascin Knockdown Decreases Invasion Ability in Glioma Cells
In Vitro and Ex Vivo
Given that there is a role for fascin in migration and adhesion, we
examined the effect of fascin knockdown on glioma cell invasion.
The invasiveness of U251, U87 and SNB19 cells was decreased fol-
lowing fascin depletion compared to untransfected cells by 52.2%
(mean ± SE, 31.8 ± 3.5 vs 66.5 ± 5.9 cells/field; P < .01), 40.3%
(47.7 ± 3.6 vs 79.9 ± 7.1 cells/field; P < .01), and 23.8% (47.9 ±
2.9 vs 62.9 ± 4.7 cells/field; P < .01), respectively. Nontargeting siRNA
transfection had no demonstrable effect on the rate of invasion in all
three glioma cell lines (Figure 6).
 
Figure 2.Morphology of glioma cells following fascin siRNA transfection. After siRNA transfection, cells were plated on laminin-precoated
coverslips for immunofluorescence. Cells were labeled with Texas Red-X phalloidin for F-actin. Fascin was labeled with anti–fascin anti-
body followed by Alexa Fluor 488–conjugated anti–mouse antibody. Arrows show staining for fascin at the leading edge in lamellipodia,
and arrowheads demonstrate filopodia bundles. Scale bar, 100 μm.
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For the ex vivo rat brain slice model system, we first demonstrated
that fascin expression was suppressed in U251-GFP cells using fascin
siRNA (Figure 7A). After 72 hours of incubation on the brain slices,
the depth of invasion of fascin-depleted U251-GFP cells was decreased
(74.2 ± 3.5 μm/72 hours) compared to control cells (94.4 ± 4.4 μm/
72 hours; P < .01; Figure 7, B and C ).
Discussion
In this study, we have shown that the actin-bundling protein, fascin,
is expressed in normal human astrocytes and permanent glioma cell
lines. Previously, we demonstrated that fascin is expressed in white
matter and cortex of normal brain. Interestingly, fascin expression in-
creased with increasing grade of astrocytoma [35,36]. In the current
study, when fascin is downregulated by siRNA, there is an associated
decrease in glioma cell adhesion, migration, and in vitro invasion.
Taken together, these results suggest a role for fascin in glioma inva-
siveness. Whereas the mechanism by which fascin knockdown reduces
glioma invasion is not entirely elucidated, we hypothesize that suppres-
sion of fascin may alter the assembly of cytoskeletal proteins, in par-
ticular actin microfilaments, in filopodia at the leading edge of motile
cells causing a reduction in cell adhesion and migration.
Fascin is principally expressed in neural and mesenchymal deriva-
tives during embryogenesis [45]. In the adult organism, fascin expres-
sion is highly tissue- and cell type–specific. For example, fascin is
expressed at high levels in the nervous system, especially in neurons,
glial cells, and vascular endothelial cells [19–22,46].
Fascin functions in two major forms of actin-based structures: cor-
tical cell protrusions that mediate cell interactions with ECM or
other cells and migration; and cytoplasmic microfilamentous bundles
that contribute to cell architecture and intracellular movements [13].
Fascin is a key filopodial bundling protein and has a central role in
the formation and protrusion of filopodia [13,15]. Vignjevic et al.
[15] determined that fascin activity is essential to filopodial dynamics
and proposed that fascin imparts rigidity to the forming filopodia to
efficiently push the membrane forward.
High-level expression of fascin has been observed in several types
of human neoplasms, such as cancer of colon [26,29,33], breast [24],
lung [27], kidney [32], ovary [30], cervix [47], and esophagus
[28,31]. In node-negative invasive hereditary breast carcinomas, fas-
cin is frequently expressed in BRCA1-associated tumors [48]. Zhang
et al. [49] observed that breast cancer metastasis suppressor, BRMS1,
expression downregulates fascin expression in ovarian carcinoma. Re-
cently, fascin has been regarded as a potential biomarker of early stage
cancer [31]. Furthermore, high fascin expression correlated with
lymph node or distant metastasis in cancers of colon, kidney, and
esophagus, and played a role as an independent marker of poor prog-
nosis [27–29,31–33,50].
Two previous studies have examined the expression of fascin in
human gliomas. Peraud et al. [35] reported fascin expression in a
panel of human gliomas and observed an increase in fascin expression
with increasing tumor grade. Roma and Prayson [36] performed im-
munohistochemical analysis in gliomas including 90 glioblastomas.
Figure 3. Inhibition of filopodia formation by fascin knockdown. Cells were seeded on laminin-coated coverslips after fascin siRNA
transfection. Actin filaments were labeled with Texas Red-X phalloidin. Arrows show filopodial bundles from cell edge in untransfected
cells. In contrast to control cells, fascin depleted U87 and SNB19 glioma cells demonstrate reduced number of filopodia. Arrowheads
indicate the residual filopodia of SNB19 cell after fascin knockdown. Bar, 25 μm.
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They also observed that the higher-grade tumors expressed a greater
degree of fascin staining than did the lower-grade tumors. Based
on these immunohistochemical data, it has been concluded that fas-
cin expression is correlated with higher-grade malignancy in human
glial tumors.
Overexpression of fascin is associated with increased cellular pro-
liferation in different cancers including non–small cell lung adeno-
carcinoma [27], colon carcinoma [26], and esophageal squamous
cell carcinoma [31]. Downregulation of fascin using RNAi resulted
in suppression of cell proliferation in esophageal carcinoma cells [34].
Jawhari et al. [26] transfected human colon adenocarcinoma cells
with a fascin cDNA and showed that fascin overexpression leads
Figure 4. The effects of fascin knockdown on glioma cell adhesion
to ECM. (A) U251, (B) U87, and (C) SNB19 cells were plated and al-
lowed to adhere for 3 hours on different ECM substrates at 72 hours
after transfection with fascin siRNA. After washing, crystal violet
bound to the attached cells were solubilized and the absorbance
was measured at 595 nm. Asterisks indicate statistically significant
change (P < .05) in adhesion after fascin silencing. Columns rep-
resent the average optical absorbance of three independent ex-
periments. Bars show SE. LN, laminin; CL, collagen type IV; VN,
vitronectin; FN, fibronectin. Figure 5. The effects of fascin knockdown on glioma cell migration
using microliter-scale radial migration assay. (A) U251, (B) U87, and
(C) SNB19 cells were transfected with siRNA and seeded through a
cell sedimentation manifold to establish a circular confluent mono-
layer on substrate-coated well. The cells were allowed to migrate for
24 hours, and photographs were taken before and after migration.
Average migration rate was calculated as the change in the diameter
of the circle circumscribing the cell population over a 24-hour period.
Asterisks indicate statistically significant changes (P < .05) in migra-
tion rate after fascin silencing. Columns represent the average mi-
gration rate of three independent experiments. Bars show SE.
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to increased dynamic cell protrusions, increased focal contacts for-
mation, increased motility, and increased invasiveness. In contrast,
downregulation of fascin using RNAi in esophageal carcinoma cells
resulted in significantly reduced cellular motility and invasive prop-
erties [28,34]. These data support our observations in human gli-
oma cells.
Previous reports have shown that the fascin–actin interaction is af-
fected by extracellular cues [13,20]. Certain ECM components induce
bundling of actin by fascin, whereas others produce inhibitory effects.
Adams [21] reported that cells exposed to thrombospondin-1 and
tenascin-C activate stable formation of fascin-containing protrusions
in fibroblasts, whereas cells that attach to fibronectin or vitronectin
show only transient cellular protrusions. It is conceivable that differen-
tial phosphorylation of fascin by ECM substrates contributes to these
observations. On a molecular basis, the actin-binding activity of fascin
is inhibited by phosphorylation of residue Ser-39 by protein kinase Cα
(PKCα) [51,52]. Cohan et al. [12] observed that treatment with the
PKC activator, 12-O-tetradecanoylphorbol-13-acetate, resulted in loss
of all actin bundles from growth cones inHelisoma. Recently, Vignjevic
et al. [15] demonstrated that dephosphorylation of Ser-39 determined
filopodial formation in mouse melanoma cells. The constitutively ac-
tive fascin mutant S39A increased the number and length of filopodia,
whereas the inactive S39E mutant did not.
Several previous reports have demonstrated that fascin silencing is
associated with changes in cellular process formation. Stable fascin
siRNA transfection of esophageal carcinoma cells led to a decrease
in filopodia formation by immunofluorescence analysis [28] and
electron microscopy [34]. Vignjevic et al. [15] showed that fascin de-
pletion leads to a reduction in the number of filopodia with the re-
maining filopodia demonstrating abnormal morphology with waxy
and loose actin bundle organization. Our study with human glioma
cells corroborates the results of these previous studies.
In attempts to clarify the mechanism by which the elimination of
fascin can lead to a reduction in cellular adhesion and migration,
Wong et al. [53] showed that ectopic constitutive expression of fascin
disrupted the dexamethasone-induced localization of occludin and
β-catenin to peripheral cell membranes. Interestingly, Vignjevic
et al. [54] showed recently that β-catenin/T cell factor signaling can
transactivate the fascin1 promoter in human colon carcinoma cells.
Xie et al. [34] demonstrated that the effect of fascin on cell invasiveness
correlated with the activation of matrix metalloproteinase-2 and -9,
and confirmed that fascin downregulation is associated with a decrease
in β-catenin and c-erbB-2 expression. Grothey et al. [24] have sug-
gested that transcriptional upregulation of fascin in human tumors is
dependent on overexpression of c-erbB-2/HER-2. However, the role
of c-erbB-2 in malignant gliomas is not clear. In one study, 80% of
Figure 6. Matrigel invasion assay after fascin elimination. (A) Modified Boyden chamber with Matrigel-precoated membrane filter insert
was used to measure in vitro invasiveness. After 24 hours of incubation, the cells that migrated through the membrane were stained,
and representative fields were photographed. Original magnification, 200×. (B) Invasion was quantified by counting cells in six random
fields. The invasion rate of the three cell lines is significantly reduced by fascin depletion. Asterisks indicate statistically significant
changes (P < .01) after fascin silencing. Columns represent the average of the number of cells per field of at least six fields in three
independent experiments. Bars show SE.
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glioblastoma cells showed expression of c-erbB-2/HER-2 [55], whereas
in another study overexpression of c-erbB-2/HER-2 was detected in
only 15% of glioblastoma tumor specimens [56].
In summary, fascin depletion in glioma cells results in decreased
filopodial formation and decreased migration suggesting that fascin
plays a key role in glioma invasiveness. The molecular mechanisms
by which fascin interacts with actin and other cytoskeletal proteins to
alter glioma cell motility, the use of a stable fascin knockdown system
in vivo, and the development of pharmacological inhibitors of fascin
will be instrumental in furthering our understanding of the role of
fascin dynamics in human malignant gliomas.
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